Experience with irinotecan for the treatment of malignant glioma

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 80-91

  Vredenburgh, James J ^a   Desjardins, Annick ^a   Reardon, David A ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EIAEDs; Glioblastoma; Irinotecan; Malignant glioma; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CARBAMAZEPINE; CARMUSTINE; CELECOXIB; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NITROSOUREA; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MEDULLOBLASTOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; OLIGODENDROGLIOMA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; THROMBOSIS; TUMOR XENOGRAFT; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DNA TOPOISOMERASES, TYPE I; GLIOMA; HUMANS;

EID: 61449210864     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-075     Document Type: Review

References (80)

1. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006;11:152-164.
2. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293-2299.
3. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Central Brain Tumor Registry of the United States. Available at http://wwwcbtrusorg/reports//2005-2006/2006report pdf 2006.
4. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006. Available at http://www.Cancer.org.
5. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31:635-644.
6. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol. 2003;30:4-9.
7. DeAngelis LM. Benefits of adjuvant chemotherapy in high-grade gliomas. Semin Oncol. 2003;30:15-18.
8. Cochrane Data. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev. 2002;(4):CD003913.
9. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from twelve randomised trials. Lancet. 2002;359:1011-1018.
10. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44:691-695.
11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
12. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006;42:582-588.
13. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12:328-331.
14. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996;56:783-788.
15. Silber JR, Bobola MS, Ghatan S, Blank A, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 1998;58:1068-1073.
16. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA- repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
17. Hegi ME, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
18. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48:403-407.
19. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 1994;20:73-96.
20. Singh S, Dwarakanath BS, Lazar MT. Role of topoisomerases in cytotoxicity induced by DNA ligand Hoechst-33342 and UV-C in a gliomas cell line. Indian J Exp Biol. 2005;43:313-323.
21. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
22. Innocenti F. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Clin Adv Hematol Oncol. 2005;3:843-844.
23. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.
24. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal car- boxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos. 1997;25:1157-1164.
25. Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer. 2003;97:2363-2373.
26. Weller M, Winter S, Schmidt C, et al. Topoisomerase-1 inhibitors for human malignant gliomas: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer. 1997;73:707-714.
27. Takeba Y, Sekine S, Kumai T, et al. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull. 2007;30:1400-1406.
28. Morandi E, Zingaretti C, Chiozzotto D, et al. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Letters. 2006;231:74-86.
29. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841-1851.
30. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyl- transferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60:6921-6926.
31. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388.
32. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1. 2007. Available at: http://www.nccn.org.
33. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer. 2006;95:131-138.
34. Camptosar [package insert]. New York, NY: Pfizer/Pharmacia & Upjohn Co. Licensed from Yakult Honsha Co., Japan, and Daiichi Pharmaceutical Co., Ltd., Japan. 2006.
35. Coggins CA, Elion GB, Houghton PJ, et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998;41:485-490.
36. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer. 1996;74:537-545.
37. Blaney SM, Takimoto C, Murry DJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 1998;41:464-468.
38. Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1- piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187-191.
39. Nakatsu S, Kondo S, Kondo Y, et al. Induction of apoptosis in multi- drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997;39:417-423.
40. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32:491-503.
41. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000;6: 2012-2020.
42. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Williston Park). 2002;16:33-40.
43. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002;8:2202-2209.
44. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421-430.
45. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2005;61:246-255.
46. Buckner JC, Reid JM, Wright K, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer. 2003;97:2352-2358.
47. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603-614.
48. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183-188.
49. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irino- tecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncol. 2002;4:102-108.
50. Cloughesy TF, Filka E, Nelson G, et al. Irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Am J Clin Oncol. 2002;25:204-208.
51. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Cancer. 2003;97:2381-2386.
52. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncol. 2004;6:21-27.
53. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and phar- macokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940-2949.
54. Prados MD, Yung WKA, Jaeckle KA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncol. 2004;6:44-54.
55. Prados MD, Lamborn K, Yung WKA, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncol. 2006;8:189-193.
56. Gilbert M, Wen P, Lieberman F, et al. Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study [abstract]. Proc Am Soc Clin Oncol. 2003;22:410.
57. Gruber ML, Buster WP. Temozolomide in combination with irinote- can for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004;27:33-38.
58. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22:4779-4786.
59. Reardon DA, Quinn JA, Rich JN, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncol. 2004;6:134-144.
60. Quinn JA, Reardon DA, Friedman AH, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncol. 2004;6:145-153.
61. Puduvalli VK, Giglio P, Groves MD, et al. Phase II trial of irinotecan and thalidomide in adult patients with recurrent glioblastoma multi- forme. Abstract TA-47. Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO), 2006.
62. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinote- can plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005;103:329-338.
63. Purow B, Fine HA. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol Oncol Clin North Am. 2004;18:1161-1181.
64. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of beva- cizumab and irinotecan in recurrent malignant gliomas. Clin Cancer Res. 2007;13:1253-1259.
65. Goli KJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas [abstract]. Proc Am Soc Clin Oncol. 2007;25:2003.
66. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
67. Raval SN, Rule A, Hwang SS. Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM). Abstract QL-29. Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO), 2006.
68. Bokstein F, Blumenthal DT. Treatment of recurrent high-grade glial tumors with bevacizumab and irinotecan: preliminary results. Abstract TA-05. Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO), 2006.
69. Cloughesy T, Prados M, Wen P, et al. A phase II, randomized, non- comparative clinical trial of bevacizumab alone or in combination with irinotecan prolongs six-month PFS in recurrent, treatment-refractory glioblastoma. Late-breaking abstract. Twelfth Annual Meeting of the Society of Neuro-Oncology (SNO), 2007.
70. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: is it useful? J Neural Neurosurg Psychiatry. 1995;58:250-252.
71. Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with F-18 FLT and positron emission tomography. Nat Med. 1998; 4: 1334-1336.
72. 18F-FDG. J Nucl Med. 2005; 46:945-952.
73. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
74. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112:1139-1146.
75. Brandes AA, Tosoni A, Amistà P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004; 63:1281-1284.
76. Burch PA, Bernath AM, Cascino TL, et al. A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs. 2000;18:275-280.
77. Lesser GJ, Grossman SA, Carson K, et al. Phase I study of karenitecin in the treatment of recurrent malignant gliomas (MG) [abstract]. Proc Am Soc Clin Oncol. 2005;23:1527.
78. Macdonald D, Cairncross G, Stewart D, et al. Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol. 1996;7: 205-207.
79. Wagner S, Erdlenbruch B, Lāngler A, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer. 2004;100:1750-1757.
80. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357-3361.